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Nrf2-dependent persistent oxidative stress results in
stress-induced vulnerability to depression
E Bouvier1,2,3, F Brouillard4,5, J Molet1,2,3, D Claverie1,2,3,6, J-H Cabungcal7, N Cresto1,2,3, N Doligez1,2,3, C Rivat1,2,3, KQ Do7, C Bernard8,
J-J Benoliel1,2,3,9,10 and C Becker1,2,3,4,10
Stressful life events produce a state of vulnerability to depression in some individuals. The mechanisms that contribute to
vulnerability to depression remain poorly understood. A rat model of intense stress (social defeat (SD), ﬁrst hit) produced
vulnerability to depression in 40% of animals. Only vulnerable animals developed a depression-like phenotype after a second
stressful hit (chronic mild stress). We found that this vulnerability to depression resulted from a persistent state of oxidative stress,
which was reversed by treatment with antioxidants. This persistent state of oxidative stress was due to low brain-derived
neurotrophic factor (BDNF) levels, which characterized the vulnerable animals. We found that BDNF constitutively controlled the
nuclear translocation of the master redox-sensitive transcription factor Nrf2, which activates antioxidant defenses. Low BDNF levels
in vulnerable animals prevented Nrf2 translocation and consequently prevented the activation of detoxifying/antioxidant enzymes,
ultimately resulting in the generation of sustained oxidative stress. Activating Nrf2 translocation restored redox homeostasis and
reversed vulnerability to depression. This mechanism was conﬁrmed in Nrf2-null mice. The mice displayed high levels of oxidative
stress and were inherently vulnerable to depression, but this phenotype was reversed by treatment with antioxidants. Our data
reveal a novel role for BDNF in controlling redox homeostasis and provide a mechanistic explanation for post-stress vulnerability to
depression while suggesting ways to reverse it. Because numerous enzymatic reactions produce reactive oxygen species that must
then be cleared, the ﬁnding that BDNF controls endogenous redox homeostasis opens new avenues for investigation.
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INTRODUCTION
Major stressful life events (for example, divorce, unemployment or
the death of a relative) do not necessarily precipitate depression,
but they can leave a trace, the allostatic load,1,2 that creates a state
of vulnerability to depression. Depending upon the level of
vulnerability, subsequent stressful events may trigger depression.3
Treating vulnerable individuals during the prodromal phase could
be highly beneﬁcial and easier to do than after the onset of
depression. Treating vulnerability to depression requires the
knowledge of its underlying mechanisms, which may be different
from those already identiﬁed for depression itself. To achieve this
aim, it is necessary to have access to (i) two populations with
different allostatic loads (but not displaying depression) and (ii) a
biomarker to distinguish between the two populations. Experi-
mental procedures have been designed to produce different
allostatic loads in rodents. Social defeat (SD), which has been used
as a major stressful event,4–6 can induce this situation.4,5 SD, as a
ﬁrst hit, generates a state of vulnerability to depression in more
than 40% of SD exposed Sprague-Dawley rats (vulnerable, V),
while the rest of the population is identiﬁed as non-vulnerable
(NV), since it is only after chronic mild stress (CMS—second hit), a
month following SD, that V, but not NV, animals will display
depression-like behavior.5 Hence, following a SD, V animals have
a higher allostatic load than NV animals. Importantly, low serum
brain-derived neurotrophic factor (BDNF) levels reliably identify
V animals after the ﬁrst hit5 as reported in human.7–9 This experi-
mental protocol thus provides an ideal situation to study the
mechanisms of vulnerability to depression since we have access to
two populations with different allostatic loads and to a predictive
biomarker at a stage when none of the animals express a
depression-like phenotype (that is, after SD, but before CMS).
We hypothesized that oxidative stress would be a central
mechanism to vulnerability to depression because hippocampal
CA3 pyramidal cells display permanent dendritic retraction and
spine loss in V animals,5 a typical signature of oxidative stress.10 In
keeping with this hypothesis, stressful life events generate a high
level of oxidative stress.11–13 Oxidative stress is the result of an
imbalance between oxidant production and antioxidant mechan-
isms that leads to oxidative damage, including lipid peroxidation
and DNA oxidation.14 A number of detoxifying (antioxidant)
enzymes, including Cu-Zn superoxide dismutase (Cu-Zn SOD),
peroxiredoxins (Prxs), catalase and glutathione peroxidases (GPxs),
prevent such damage by limiting the accumulation of reactive
oxygen species (ROS).15,16 On the basis our hypothesis, we can
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make three predictions. First, one or several of these detoxifying/
antioxidant enzymes are dysfunctional in V animals, thus
generating oxidative stress. Second, the mechanisms regulating
these enzymes are downregulated. Among these mechanisms, we
focused on the Nrf2/Keap1 pathway, which is a master regulator
of redox homeostasis.17,18 Nrf2 is usually retained in the cytosol,
where it is tethered to its cytosolic repressor, Kelch-like ECH
associated protein-1 (Keap1).17,18 When Nrf2 dissociates from
Keap1, it translocates to the nucleus and binds to antioxidant
response elements on target genes to activate antioxidant
defenses.18,19 This redox-sensitive transcription factor controls
the expression of sulﬁredoxin,20 an important regulator of
peroxiredoxin activity,21 which catalyzes the Prx-2-SO2H reduction,
thus regenerating the active enzyme, Prx-2.18,22 Our choice of
Nrf2 is justiﬁed because its dysfunction produces a redox
imbalance in neurodegenerative, cardiovascular, pulmonary and
chronic inﬂammation,19,23 which can lead to a depression-like
phenotype.24,25 The third prediction is that BDNF, which levels
remain low in V animals, is causally related to oxidative stress.
Here, using a longitudinal study, we demonstrate that low BDNF
levels prevent the activation of Nrf2-dependent endogenous
antioxidant peroxiredoxin/sulﬁredoxin defense mechanisms, lead-
ing to sustained oxidative stress in vulnerable animals. Reactivat-
ing these defense mechanisms restores redox homeostasis and
abolishes vulnerability to depression.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats weighing 290–310 g (9 weeks old at the
beginning of the experiments) were obtained from the Centre d'Elevage R.
Janvier (53940 Le Genest-St-Isle, France) and used as intruder rats. We used
male Sprague-Dawley rats from the same litter. From each litter, some rats
were selected randomly as controls, and the others were subjected to
repeated SD (see below).
Male wild-type Groningen (WTG) rats were used as resident rats.26
Wild-type (Nrf2+/+) and Nrf2-null (Nrf2− /− ) mice were used to conﬁrm
the role of Nrf2. Nrf2-null mice were backcrossed onto the C57BL/6J
background for seven generations using alternating male and female stock
mice from the CNRS TAAM UPS44 (Orléans). The resulting wild-type (Nrf2
+/+) and Nrf2-null (Nrf2− /− ) mice were genotyped and only male mice at
6 weeks old at the beginning of the experiments were used. They were
exposed to CMS only.
All animals (rats or mice) were housed in chronobiological animal
facilities equipped with regularly spaced, soundproof, temperature-
controlled compartments and supplied with ﬁltered air. Procedures
involving animals and animal care protocols were performed in
accordance with institutional guidelines that conformed to national and
international laws and policies. For more details, please see the information
in the Supplementary Materials and Methods.
Social defeat procedure in rats
The social defeat procedure (SD) (D-3 to D0) was performed on rats as
previously described.5,27,28 This procedure involved subjecting the same
pairs of residents and intruders to four daily sessions (Figure 1a).
The 45 min sessions were divided into two consecutive periods.
During period I (30 min), intruders were placed individually in a protective
cage within the resident animal’s home cage. The protective cage
allowed unrestricted visual, auditory and olfactory contact with the
resident but prevented close physical contact. During period II (15 min),
the protective cage was removed, either with the resident remaining
present, which allowed for physical confrontation with the intruder (3–4
confrontations of ~ 10 s, during each of which the intruding (defeated)
animal was always dominated by the resident rat) or with the resident
removed, which gave the intruder access to the entire resident home cage
(control intruders). The control intruders were therefore never physically
attacked and defeated by the resident and did show any sign of
stress and/or anxiety.27,28 Animals that were wounded as a result of
the SD procedure were excluded from the experiment (2% of stressed
animals).
Serum BDNF assay
Blood samples (200 μl) were collected from conscious rats between 1200
and 1230 hours at key times (D-4, D5, D11 and D31). These samples were
taken from the tail vein and were collected in Eppendorf tubes.5
The samples were centrifuged to separate the serum, which was stored
at − 20 °C until BDNF analysis. BDNF concentrations were determined at a
dilution of 1:25 with a commercial BDNF assay (Promega, Charbonnières-les-
Bains, France). The measurement of serum BDNF levels was performed after
all other experiments and analyses were performed. Thus, the investigators
were blind to the classiﬁcation of animals based on BDNF level, which was
the last parameter to be measured during the experimental procedure and
analyses.
Proteomic approach
To investigate proteins related to redox homeostasis, we analyzed
hippocampal extracts in a urea-based solubilization buffer with compara-
tive two-dimensional (2D) gel analysis. Spots displaying differential
expression were identiﬁed using MALDI-TOF MS. Detailed descriptions of
our 2D gel electrophoresis and identiﬁcation protocols are provided in the
Supplementary Materials and Methods.
Redox parameters
Catalase, SOD, glutathione peroxidase, aconitase and TBARS levels were
immediately analyzed in fresh hippocampal extracts. Detailed descriptions
of extraction and assay protocols are provided in the Supplementary
Materials and Methods.
Immunoﬂuorescence staining, confocal microscopy and image
analysis
Oxidative damages were visualized in all subﬁelds of the dorsal and ventral
hippocampus using a DNA adduct formed by the reaction of OH radicals
with the DNA base guanine.29 Detailed descriptions of immunoﬂuores-
cence staining protocols, confocal microscopy and image analysis are
provided in the Supplementary Materials and Methods.
Golgi staining
Neuroanatomical alterations were analyzed in unperfused brains using the
Golgi staining method following the manufacturer’s instructions. The total
length of the apical dendrites and the density of apical dendritic spines of
selected neurons in CA3 were determined with AxioVision 4.7 software
(Marly Le Roi, France) and a Zeiss Imager M1 microscope (Marly Le Roi,
France). Detailed descriptions of the dendrite measurement protocols,
Sholl analysis and spine density assessments are provided in the
Supplementary Materials and Methods.
Western blot analysis
After nuclear and cytosolic fractionation of hippocampal tissues (extensive
details are included in the Supplementary Materials and Methods), proteins
were resolved by SDS–polyacrylamide gel electrophoresis, transferred
to nitrocellulose membranes and incubated with antibodies speciﬁc to
SOD1, Prx-2, Prx-SO2/SO3, Nrf2, Keap1, aconitase, GAPDH or β-actin.
The secondary antibodies used in these assays were either IRDye- or
horseradish peroxidase-conjugated (for further information, please see the
Supplementary Materials and Methods).
RT–PCR
After RNA extraction, real-time PCR ampliﬁcation was performed to
analyze the following target genes: sulﬁredoxin (Rn01536084-g1*) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Rn99999916-S1).
Descriptions of RNA extraction protocols and real-time PCR ampliﬁcation
conditions are provided in the Supplementary Materials and Methods.
In vivo siRNA knockdown, microinfusion and ICV administration
BDNF knockdown was performed using Silencer Select Ambion in vivo
siRNA targeting BDNF (with additional chemical modiﬁcations for superior
stability, Invitrogen, Courtaboeuf, France) or a non-targeting Silencer
Select Ambion in vivo siRNA as a control (Invitrogen). A week before
siRNA transfections, rats were anesthetized with ketamine (33 mg kg− 1)
and xylazine (6 mg kg− 1) and were placed in a stereotaxic apparatus
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(Kopf Instruments, Phymep, Paris, France). Two stainless steel cannulas
(Plastic One, Phymep, Paris, France) were implanted bilaterally in the dorsal
hippocampus at the following stereotaxic coordinates with respect to
bregma: − 4.8 mm anteroposterior, ± 3.2 mm mediolateral and − 2.2 mm
dorsoventral (from dura mater, histological location of canula was veriﬁed
in two sham animals, see Supplementary Figure S1a). The cannulas were
anchored to the skull using acrylic dental cement. Control siRNA and BDNF
siRNA (ﬁnal concentration of 50 μM, Ambion—48 h stability—, InVitrogen)
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were prepared using Invivofectamine 2.0 according to the manufacturer’s
forward protocol (Invitrogen). Animals received two injections of control or
BDNF siRNA 2 days apart and were killed 48 h later. Each hippocampus
received 1 μl of solution at a ﬂow rate of 0.25 μl min− 1. The injection
needle was left in situ for 5 min post injection and then slowly removed.
The brain of the animals was removed and the hippocampi were dissected
to obtain nuclear and cytosolic extracts after subcellular fractionation.
BDNF siRNA efﬁciency was 62%: BDNF levels were 5.73 ± 0.17 pg mg− 1
with control siRNA and 2.17 ± 0.06 pg mg− 1 with BDNF siRNA.
For microinjection of BDNF, rats were anesthetized with ketamine and
xylazine. Two stainless steel cannulas (Plastic One) were implanted in each
dorsal hippocampus (as above). Infusions of 1 μg BDNF, or of vehicle, were
performed during 1 h. Subcellular fractionation was performed as above.
For intracerebroventricular delivery with osmotic minipumps, we
prepared tert-Butylhydroquinone (t-BHQ, Sigma) at a ﬁnal concentration
of 1 mM in vehicle (1% EtOH in H2O).
30 Alzet osmotic minipumps
(Charles River Laboratories, L’Arbresle, France) were ﬁlled with a fresh
solution of t-BHQ and were connected to a 26-gauge stainless steel
cannula implanted in the right lateral ventricle (stereotaxic coordinates
with respect to bregma: 1 mm caudal; − 1.5 mm lateral; − 3.4 mm below
the surface) for continuous infusion during 6 (t-BHQ) or 7 (vehicle) days.
Administration of t-BHQ started 6 days before the onset of the CMS
protocol.
Superfusion of the hippocampus
Hippocampi were cut into eight pieces, placed in the tissue chamber for
perfusion, and suspended in artiﬁcial cerebrospinal ﬂuid (pH 7.3). After 1 h
of superfusion,31 the tissue was collected and subjected to subcellular
fractionation. The details of the superfusion procedure are provided in the
Supplementary Materials and Methods.
Two-hit procedure
Sprague-Dawley rats were subjected to SD (ﬁrst hit), and then, 4 weeks
later, to 3 weeks of CMS (second hit) (Figure 1a). The CMS protocol was
performed as previously described.5 The control rats (C rats) were control
intruders (not subjected to SD) that were not exposed to CMS.
Chronic mild stress protocol
The CMS protocol is described in the Supplementary Materials and
Methods.
Phenotypic analyses
The depressive phenotype of the animals was determined by analyzing
immobility time in the forced swimming test, the amount of liquid
consumed in the sweet water consumption test, the activity of the HPA
axis (serum corticosterone levels and adrenal gland weight) and body
weight. Detailed protocols used in the forced swimming and sweet water
consumption tests and to acquire measurements of HPA axis activity are
extensively described in the Supplementary Materials and Methods.
Drugs and treatments
The antioxidant compound, Tempol (4-hydroxy-2,2,6,6-tetramethylpiper-
idine 1-oxyl; 288 μmol kg− 1 day− 1),32,33 was dissolved in distilled water
and delivered via ALZET osmotic minipumps. 7-8-dihydroxyﬂavone
(7,8-DHF; 5 mg kg− 1)34 was dissolved in sterile 0.9% NaCl solution adjusted
to pH 7 with 0.1 M NaOH and administered (i.p.) on days 5, 7 and 9 after the
end of the SD protocol (D5, D7 and D9). For ICV administration, a
prototypical compound that induces the nuclear translocation of Nrf2,
t-BHQ (1 mM),18,30 was dissolved in 1% EtOH/distilled water and
delivered via ALZET osmotic minipumps. For superfusion experiments,
7,8-DHF (10− 5 M) was diluted in artiﬁcial cerebrospinal ﬂuid. For more
details regarding the drugs and treatments used, please see the
Supplementary Materials and Methods.
Statistical analyses
Classiﬁcation of animals into NV or V was performed using the k-means
clustering method with Statistica.35 Differences in SOD activity, TBARS
levels, aconitase activity or quantity, glutathione peroxidase activity,
catalase activity, peroxiredoxin-2, peroxiredoxin SO2/SO3, the marker 8-
oxoDG, the gene expression of nuclear Nrf2, cytosolic Nrf2, cytosolic
Keap1, and sulﬁredoxin, immobility time, anhedonia, HPA axis activity,
hippocampal BDNF levels, and the apical dendrite length of CA3 neurons
and hippocampal CA3 dendritic spines were evaluated by one-way analysis
of variance (ANOVA). Serum BDNF concentrations or body weight were
analyzed by one-way ANOVA for repeated measures. Stress effects and
treatment effects were evaluated by two-way ANOVA. All results from
ANOVA analyses (F-values and P-values) are provided in Supplementary
Tables 1 and 2. When an ANOVA revealed a signiﬁcant effect, a pair-wise
post hoc Bonferroni test was performed. No statistical methods were used
to predetermine sample sizes, but our sample sizes are similar to those
generally employed in comparable studies. All data are presented as the
mean± s.e.m.
RESULTS
Oxidative stress in vulnerable animals
If oxidative stress contributes to vulnerability to depression,
markers of oxidative stress should be present in V but not in NV
rats. Hippocampal tissues from both groups were analyzed thirty-
one days after SD (D31), when V and NV animals can be
distinguished based on their serum BDNF levels5 and do not
present anymore an anxious or a depression-like phenotype
Figure 1. Oxidative stress in vulnerability to depression. Restoration of redox homeostasis and reversion of the phenotype of vulnerability with
antioxidant treatment. (a) The experimental 'double-hit' design involved subjecting rats to SD (D-3-D0) followed, 4 weeks later, by CMS.
Evaluation of redox parameters was performed 5 days (D5), 11 days (D11) and 4 weeks (D31) after the end of the social defeat procedure.
Neuroanatomical parameters were measured at D11 and D31. Depression-like phenotype (helplessness behavior, decrease in sweet water
consumption, HPA, body weight) was evaluated at D31 and at the end of the double-hit procedure, at D53. Animals were treated with 7,8-DHF
or with Tempol: 1- for 7,8-DHF treatment, administrations were performed at D5, D7 and D9; 2- a 15-day-long treatment with Tempol started
11 days after SD (D11). (b) Oxidative stress results in lipid oxidative damage (lipid peroxidation, MDA) and in decreased activity of the sensitive
redox aconitase in vulnerable (V, n= 6–8) rats, but not in NV (n= 7–8) animals, 31 days after the end of the SD procedure (D31). (c) The quantity
and activity of SOD, which catalyzes the ROS hydrogen peroxide (H2O2) production and of the antioxidant systems involved in the reduction of
ROS H2O2 to water, peroxiredoxin-2 (Prx-2) and its inactive form (Prx-sulﬁnic [SO2]/sulfonic [SO3]), glutathione peroxidase (GPx) and catalase
activities, were evaluated in V animals and NV animals. The peroxiredoxin-2 antibody targets both the active and inactive forms of the enzyme
(total). The Prx-SO2/SO3 antibody targets the inactive form of enzyme. SOD activity and the inactive form of Prx-2 were increased in V animals
indicating oxidative stress. (d) Effects of a 15-day-long treatment with Tempol starting 11 days after SD (D11), when vulnerable (V) could be
identiﬁed based on serum BDNF levels. Tempol normalized all signs of oxidative stress in V animals to control and NV levels. Tempol prevented
lipid oxidative damage, decrease in aconitase, increase in SOD, and restored the active form of peroxiredoxin-2 (Prx-2). Glutathione peroxidase
(GPx) and catalase activities were not affected (C: n= 5–6; NV: n= 6–8; V: n= 5–6). (e) Tempol restored anatomical integrity (total apical dendrite
length and spine density) of CA3 hippocampal neurons in V animals (n= 4–5). (f) Tempol prevented the appearance of a depression-like
phenotype of V animals after CMS as assessed by immobility time in the forced swim test, sweet water consumption and activity of HPA axis (C:
n= 6–8; NV: n= 10; V: n= 7–9). See also Supplementary Figure S1d for proteomic analysis 31 days after SD. The results of statistical analyses are
presented in Supplementary Table S1A1-2. *Po0.05 vs C animals; aPo0.05 vs NV group; †Po0.05 vs the corresponding Tempol-treated group.
BDNF, brain-derived neurotrophic factor; CMS, chronic mild stress; DHF, dihydroxyﬂavone; HPA, hypothalamic–pituitary–adrenal hyperactivity;
NV, non-vulnerable; ROS, reactive oxygen species; SD, social defeat; SOD, superoxide dismutase.
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(Supplementary Figure S1b,c).5 We found lipid oxidative damage
(indicated by increased lipid peroxidation) and a decrease in the
activity of aconitase, an intracellular enzyme highly sensitive to
pro-oxidant conditions,36 speciﬁcally in V animals (Figure 1b).
Two-dimensional gel proﬁling revealed differences in the
expression of eleven abundant proteins that were clustered into
four main functional categories according to in silico analysis with
GO Term Finder37 (Supplementary Figure S1d). One category
included SOD and Prx-2 and Prx-6, which are enzymes involved in
the regulation of ROS levels. Consistently with this proteomic
approach, subsequent biochemical analyses showed that the
quantity and activity of SOD, an inducible enzyme that catalyzes
the reduction of the ROS superoxide radical (O2
•-) to the ROS
hydrogen peroxide (H2O2),
38 were higher in V than in NV animals
(Figure 1c). Prx-2, which is part of a major enzymatic system
that is involved in the reduction of the ROS H2O2 to water, was
present primarily in its inactive form, Prx-sulﬁnic/sulfonic (SO2/
SO3), in the hippocampi of V animals. However, there was no
signiﬁcant change in its overall level of expression (Figure 1c). In
contrast, the activity of both GPx and catalase remained
unchanged in V and NV animals (Figure 1c). These results suggest
that an increase in the inactive form of Prx-2 leads to defective
H2O2 clearance in the hippocampi of V animals (thereby inducing
oxidative stress). The levels of H2O2 could not be measured
directly, because H2O2 cannot be accurately quantiﬁed in ex vivo
brain material.39 If oxidative stress is causally related to vulner-
ability to depression, antioxidant treatment should reverse this
vulnerability phenotype.
Vulnerability to depression after SD is due to oxidative stress
We used Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidinoxyl), an
antioxidant compound that promotes the metabolism of many
ROS33 to treat V and NV rats. As expected, Tempol reduced GPx
levels33 and fully reestablished redox homeostasis in V animals
(Figure 1d). We have previously shown that both the length of
apical, but not basal, CA3 pyramidal cell dendrites and the number
of spines are consistently decreased in V animals.5 Since such
alterations can sign cellular oxidative stress,40 we used them as
anatomical markers. Tempol treatment fully normalized the lenght
of apical dendrites and the number of spines to control levels
(Figure 1e and Supplementary Figure S1e). Finally, Tempol
abolished vulnerability to depression. Increased immobility times
in the forced swimming test, decreased sweet water consumption
and HPA axis hyperactivity (corticosterone levels, adrenal gland
weight) observed in vehicle-treated V animals were prevented by
Tempol treatment in V animals, following the second hit
(Figure 1f). In NV animals, CMS protocol induced a small increase
of corticosterone levels5 that was not prevented by Tempol
treatment. Together, these results demonstrate that, in this
double-hit experimental model, oxidative stress is responsible
for the vulnerability to depression, and that such vulnerability can
be reversed with an antioxidant treatment.
Longitudinal study of oxidative stress status
Oxidative stress was identiﬁed at 31 days after SD in V animals,
which suggests two possible scenarios: (i) a gradual buildup of
oxidative stress or (ii) a long-lasting state triggered by the ﬁrst hit.
We thus performed a longitudinal study to distinguish between
these two possibilities. A state of oxidative stress was present in all
animals at D5 (Supplementary Figure S2a), which is a classical
characterization of an acute response to an intense stressor.12,13
We then assessed oxidative stress at D11, when V and NV animals
can ﬁrst be distinguished based on serum BDNF levels (Figure 2a).
Animals identiﬁed as V at D11 remained V at D31 (Figure 2a),
whereas control (C) animals maintained constant levels of BDNF
throughout. On D11, V animals displayed increased SOD activity,
enhanced levels of the inactive form of Prx-2 (Figure 2b) and
decreased aconitase activity (Supplementary Figure S2b), which
should result in H2O2 accumulation and oxidative stress. A state of
oxidative stress was directly conﬁrmed by the presence of high
levels of lipid peroxidation (MDA) and DNA oxidation (using 8-oxo-
dG as a marker) in the hippocampus of vulnerable animals
(Figures 2c and d). Oxidative stress in vulnerable animals was
mostly found in neurons (Figure 2e). In contrast, SOD activity
returned to normal, levels of the inactive form of Prx-2 decreased
and oxidative damage disappeared by D11 in NV animals
(Figures 2b–d and Supplementary Figure S2b). From these results,
we conclude that the acute oxidative stress response triggered by
the ﬁrst hit was maintained in V animals but disappeared in NV
animals. Because Prx-2 activity has a key role in maintaining redox
homeostasis,41 we next explored the mechanisms underlying its
long-term inactivation.
Dysfunction of the Nrf2 pathway causes vulnerability to
depression
The active form of Prx-2 is regenerated by sulﬁredoxin.21
Sulﬁredoxin mRNA levels were decreased in V animals and
increased in NV animals compared with controls on D11
(Figure 2f), suggesting that transcriptional downregulation of
sulﬁredoxin contributed to the accumulation of the inactive
form of Prx-2 in V animals, whereas its upregulation in NV animals
contributed to detoxiﬁcation. The transcription of sulﬁredoxin is
controlled by the redox-sensitive transcriptional factor Nrf2,20,22 a
master regulator of redox homeostasis.17,18 At D5, all experimental
animals had lower nuclear levels of Nrf2 than controls (Figure 2g),
in keeping with decreased levels of sulﬁredoxin (Figure 2g),
increased levels of the inactive form of Prx-2 (Supplementary
Figure S2a), and a state of oxidative stress (Supplementary
Figure S2a). At D11, nuclear Nrf2 levels were signiﬁcantly
increased in NV animals as compared with controls (Figure 2f),
indicating the activation of antioxidant defenses. In contrast, Nrf2
nuclear levels remained decreased in V animals, which may have
induced a permanent state of oxidative stress and vulnerability to
depression in these animals. If the Nrf2 pathway is causally linked
to vulnerability to depression, impairment of Nrf2 would produce
vulnerability to depression. To test this hypothesis, we ﬁrst
evaluated the behavior of Nrf2+/+ mice in avoidance test after
10 days social stress predicting that Nrf2+/+ mice can also be split
into two populations4 (see Supplementary Figure S2f). Secondly,
we used Nrf2-null mice predicting that they would be endogen-
ously vulnerable, that is, a minor stressor (CMS) should be
sufﬁcient to trigger a depression-like phenotype.
Nrf2 downregulation is sufﬁcient to cause vulnerability to
depression
Nrf2-null mice were constitutively characterized by oxidative stress
(Figure 3a) and by anatomical alterations in CA3 pyramidal cells
(Figure 3b). These were abolished by Tempol treatment
(Figure 3b). Hippocampal BDNF levels were not signiﬁcantly
different in Nrf2-null mice compared with Nrf2+/+ mice
(1.71 ± 0.06 pg mg− 1 tissue (n= 6) compared with
2.12 ± 0.26 pg mg− 1 tissue (n= 5), respectively). Nrf2-null mice
did not display a depression-like phenotype. Their immobility
times in the forced swim test and the activity of their HPA axes
were similar to those observed in Nrf2+/+ mice (Figure 3c). Sweet
water consumption was also similar between Nrf2+/+ and Nrf2-
null mice (6.6 and 7.4 ml per day, respectively). However, when
exposed to three weeks of CMS, Nrf2-null mice developed a
depression-like phenotype that included helplessness behavior,
anhedonia and HPA hyperactivity, all of which were prevented
by pretreatment with the antioxidant Tempol (Figure 3c).
Nrf2-null mice are thus endogenously vulnerable to depression,
sharing the phenotypic traits of V rats (including an endogenous
state of oxidative stress). The depressive phenotype of
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Nrf2-null mice can be revealed by exposure to a minor stressor
(CMS). We conclude that the downregulation of Nrf2 is sufﬁcient
to cause vulnerability to depression.
Nrf2 downregulation is necessary to cause vulnerability to
depression
If the downregulation of Nrf2 constitutes a necessary condition
for vulnerability to depression, inducing its translocation
should abolish vulnerability to depression. We thus used V
and NV rats and administered t-BHQ, a prototypical compound
that induces the nuclear translocation of Nrf218 (Supplementary
Figure S2g). Treatment with t-BHQ abolished vulnerability
to depression in V rats (Figure 3d). We conclude that
altered Nrf2 function is necessary and sufﬁcient for maintaining
a long-lasting state of oxidative stress and vulnerability to
depression.
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Upstream regulation of Nrf2
In the double-hit scenario tested here, we demonstrated (i) that a
sustained state of oxidative stress caused vulnerability to
depression (since the latter could be reversed by the administra-
tion of detoxifying agents), and (ii) that Nrf2 dysfunction was
responsible for the sustained state of oxidative stress (since
inducing Nrf2 translocation reversed oxidative stress and the
vulnerability state). We therefore investigated which upstream
mechanisms may be responsible for the long-term downregula-
tion of Nrf2. The candidate mechanism should follow the time
course of Nrf2/oxidative stress alterations, that is, it should be
altered during the acute phase after SD, it should persist in V
animals, and it should be resolved in NV animals. In addition,
detoxiﬁcation (as a downstream effector), although restoring a
control behavioral phenotype, may not necessarily affect this
upstream mechanism. BDNF fulﬁlls these requirements. Its serum
levels, which reﬂect hippocampal BDNF concentrations,5,42
showed the same time course as Nrf2/oxidative stress alterations
(Figure 2a). In addition, BDNF levels were not modiﬁed following
the restoration of redox homeostasis suggesting that oxidative
stress does not affect BDNF levels (Supplementary Figure S2h). We
thus explored the possibility that BDNF may directly regulate Nrf2.
BDNF controls the stability of the redox-sensitive Nrf2 pathway
If the hypothesis that BDNF directly regulates Nrf2 is correct,
altering BDNF levels should modify the amount of Nrf2 transloca-
tion. This hypothesis was tested in vivo. Microinjections of BDNF
siRNA in rat hippocampi decreased Nrf2 translocation to the
nucleus and caused oxidative stress (Figure 3e). In contrast, no
such modiﬁcations were induced by microinjections of control
siRNA or saline (Figure 3e). Conversely, in vivo microinjection of
BDNF into the rat hippocampi increased Nrf2 translocation to the
nuclear compartment (Figure 3f). Since direct in vivo down- and
upregulation of BDNF decreases and increases Nrf2 translocation,
respectively, we propose the following putative molecular cascade
to explain vulnerability to depression in the double-hit scenario
studied here. Low BDNF levels prevent sufﬁcient translocation of
Nrf2 to the nucleus, resulting in decreased Prx-2/Sulﬁredoxin-
dependent detoxifying activity. This produces the oxidative stress
state that is responsible for vulnerability to depression. If this
scheme is correct, upregulating BDNF should abolish the
vulnerability state of V animals.
This hypothesis could not be directly tested because of the
unsuitable pharmacokinetic proﬁle and adverse long-term side
effects triggered by direct injections of BDNF.43 We thus tested
7,8-DHF, a ﬂavone, which has been identiﬁed as a selective TrkB
agonist, but which can act independtly as a potent antioxidant to
protect cells against glutamate or H2O2-induced oxidative
injury.44–46 Perfusion of hippocampal tissues extracted from
control and SD rats with 7,8-DHF (10 μM) induced a marked
increase in the translocation of Nrf2 to the nuclear compartment
(Figure 3g). Since administration of 7,8-DHF can restore Nrf2
translocation, we predicted that treating V animals with 7,8-DHF
would abolish their state of vulnerability.
Reversal of vulnerability to depression
Systemic injections of 7,8-DHF normalized Nrf2 translocation to
the nuclear compartment in V animals to NV and control levels,
restored normal levels of (i) sulﬁredoxin gene expression
(Figure 4a), (ii) the active form of Prx-2 (Figure 4b), (iii) DNA
oxidation (Figure 4c) and (iv) lipid peroxidation (Supplementary
Figure S3d). Treatment with 7,8-DHF also normalized anatomical
alterations of CA3 pyramidal cells (Figure 4d). Finally, 7,8-DHF
treatment in V animals abolished their vulnerability to depression
since they did not display phenotypic traits of depression after
CSD (Figure 4e). Thus, treatment with 7,8-DHF restored Nrf2
translocation, reinstated redox homeostasis and abolished vulner-
ability to depression.
DISCUSSION
SD during the acute phase (5 days after the end of SD, Figure 5)
produces an oxidative stress response that manifests as SOD
hyperactivity and an increase in the inactive form of Prx-2,
resulting in lipid damage. Prx-2 is an antioxidant enzyme involved
in H2O2 reduction. Catalytic H2O2 reduction by this typical 2-Cys
Prx involves the oxidation of its redox-active peroxidatic cysteine
into a sulfenic acid (Cys-SOH), which can be recycled via the
formation and reduction of an intermediate disulﬁde bond.41 Prx-2
is itself sensitive to inactivation by high levels of H2O2 through the
oxidation of its peroxidatic cysteine to a sulﬁnic (–SO2H) or
sulfonic (–SO3H) acid form.
47 Thus, overoxidation of Prx-2 favors
H2O2 accumulation and redox imbalance.
48 Prx-2 is strongly
expressed in neurons, especially in the hippocampus.41 Dysfunc-
tion of Prx-2 leads to oxidative stress and cell damage in
neurodegenerative diseases.41,49 The increase in the Prx-2 inactive
form observed just after SD is consistent with the depleted
antioxidant levels and altered antioxidant enzyme activities that
have been measured in various acute or chronic models of stress,
including models of immobilization stress, swim stress, CMS and
SD.12,13 This downregulation could be a compensatory response
or an essential phase that protects against deleterious chronic
stress-related events rather than a maladaptive response.50,51
Following the initial acute phase of redox imbalance, oxidative
stress disappeared in NV animals by D11 but persisted in V
animals (Figure 5). This ﬁnding and the observation that the
Figure 2. Dysfunction of the redox-sensitive transcription factor Nrf2 in vulnerable animals. (a) Longitudinal follow-up of serum BDNF levels
leading to the identiﬁcation of NV and V rats already 11 days after SD (D11). (b) At D11, only V animals showed increased SOD activity and
increase in the inactive form of Prx-2 (C: n= 5–6; NV: n= 6–8; V: n= 5–6), as at D31. (c and d) Oxidative damages estimated with lipid
peroxidation [MDA, c] and DNA oxidation [8-oxo-dG marker, d] in ventral and dorsal hippocampi of NV (n= 5–8), V (n= 4-6) and control (n= 5–
6) animals at D11. MDA analysis also revealed increased levels of lipid peroxidation in V animals. Upper panel: Immunoﬂuorescence
micrographs illustrating speciﬁc DNA oxidation in all subﬁelds of the ventral hippocampus of V animals as compared with NV and controls
(Dentate Gyrus: DG, CA3, CA1). Scale bars, 100 μm. (lower) Quantitative analysis showing DNA damage in ventral and dorsal hippocampi of V
animals. DNA damage was speciﬁcally observed in V animals. (e) 1- Pictomicrograph of co-immunolabeling for NeuN (blue), GFAP (red) and 8-
oxo-dG (green) in V animals. 2- Pictomicrograph with increased magniﬁcation. V rats showed 8-oxo-dG (green) immunolabeling in neurons
(NeuN, blue) and some glial (GFAP, red) cells. Scale bar: 30 μm. (f) The levels of sulﬁredoxin mRNA—an adjunct of peroxiredoxin system
regenerating the active enzyme—were increased in NV but decreased in V animals as compared with controls. Nuclear levels of Nrf2 were
increased in NV but decreased in V animals as compared with controls (C: n= 7, NV: n= 7; V: n= 6). These results suggest activation of
antioxidant defense mechanisms in NV and their failure to activate in V animals. (g) The levels of sulﬁredoxin mRNA and nuclear Nrf2 in
hippocampi were decreased in animals at 5 days after SD. (SD, n= 6) and control animals (C, n= 6). The results of statistical analyses are
presented in Supplementary Table S1 B1-2. *Po0.05 vs C animals; aPo0.05 vs NV group. See also Supplementary Figure S2 for oxidative
stress; cytosolic Nrf2 and Keap1 in animals 5 and 11 days after SD; microglia and phagocytic microglial immunolabeling; repeated social
stress in mice; t-BHQ effect; hippocampal BDNF levels 5 and 31 days after SD and Supplementary Table S2 B1-5 for statistical analysis.
BDNF, brain-derived neurotrophic factor; NV, non-vulnerable; SD, social defeat; SOD, superoxide dismutase.
BDNF, oxidative stress and vulnerability to depression
E Bouvier et al
7
Molecular Psychiatry (2016), 1 – 13
vulnerable state can be suppressed by treatment with antiox-
idants leads us to propose that an unresolved state of oxidative
stress leads to vulnerability to depression in the double-hit
scenario tested here. This scheme is similar to that proposed for
inﬂammatory diseases, in which acute inﬂammatory processes
need to be cleared to avoid a chronic state.52 Our results are
consistent with the channel oxidation hypothesis of depression-
like behaviors, which can be reversed by the administration of
Tempol.53
We demonstrate that Nrf2 is a key regulator of oxidative stress
following SD. Dysfunction in the Nrf2/Keap1 pathway produces
redox imbalance in neurodegenerative, cardiovascular, and
pulmonary diseases as well as chronic inﬂammation.19,23 Until
now, the involvement of Nrf2 in stress-related disorders had not
been described. Here, we show that the downregulation of
nuclear Nrf2 caused a decrease in its transcriptional activity, as
indicated by decreased sulﬁredoxin mRNA levels. Because
sulﬁredoxin catalyzes the recycling of overoxidized-Prx-2, the
BDNF, oxidative stress and vulnerability to depression
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downregulation of sulﬁredoxin caused by the decrease in nuclear
Nrf2 explains the signiﬁcant accumulation of the overoxidized/
inactive form of Prx-2 and the permanent state of oxidative stress.
The decreased translocation of Nrf2 thus prevents the efﬁcient
activation of antioxidant defense mechanisms, which favors redox
imbalance. Conversely, recovery in NV animals is made possible by
an increase in Nrf2 translocation into the nucleus and the
subsequently increased sulﬁredoxin levels, which, in turn,
increases the Prx-2-dependent detoxiﬁcation of H2O2
produced by SD.
In examining the upstream mechanisms that control Nrf2, we
made the unexpected discovery that BDNF can act as a
homeostatic regulator of Nrf2 activity by increasing its nuclear
translocation. Despite intense scrutiny in cancer research studies,
the precise mechanisms that control Nrf2 translocation remain
poorly understood.54 It is therefore difﬁcult to propose a
mechanism by which BDNF controls the Nrf2 pathway. Never-
theless, we have found that BDNF tonically induces Nrf2
translocation into the nucleus under basal conditions, thereby
constantly activating antioxidant mechanisms. Because numerous
enzymatic reactions produce ROS, which must then be cleared, we
propose that the BDNF-Nrf2 pathway is part of the normal
detoxiﬁcation processes that are continuously activated in cells.
During the acute phase (D5), all animals displayed pro-oxidant
conditions due to a BDNF-dependent failure to activate Nrf2-
dependent antioxidant defenses. However, we cannot exclude the
possibility that other transcription factors were involved in this
mechanism of redox homeostasis. At D11, BDNF levels were
restored in NV animals, and the Nrf2 system showed signs of
hyperactivity while oxidative balance was restored (Figure 5). The
lower levels of BDNF in the V animals prevented Nrf2 from
restoring normal redox conditions (Figure 5). Our results suggest
that the resolution of the initial phase of oxidative stress is an
active process that involves multiple steps, including the activity
of a regulator molecule, BDNF, and a transcription factor, Nrf2, to
control the expression of antioxidant enzymes.
Anatomical alterations of the hippocampus are a hallmark not
only of animal models of depression and psychosocial stress55–57
but also of animals that are vulnerable to depression.5 Here, we
focused on the CA3 area. Since oxidative stress extends to other
hippocampal subﬁelds, anatomical alterations may also affect
other hippocampal cells. In the present study, we show that failure
of Nrf2 to translocate to the nucleus is causally linked to
anatomical alterations. Nrf2-null mice displayed endogenous
reduction of apical dendritic length as V rats.5 Similar Nrf2-
dependent mechanisms may be at play in neurodegenerative
diseases, including Alzheimer’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis, which are characterized by oxidative
stress and anatomical alterations.58,59 Using a proteomic
approach, we identiﬁed abnormal expression patterns of proteins
known to be involved in cell morphology, cell projection/
organization, and the regulation of protein ser/thr kinase activity.
Most of these proteins, including DPYL2, RhoGDI, CapZ beta,
PP2A-alpha, UCHL1, HSC71 and enolase, are prone to oxidative
modiﬁcations.60–63 If anatomical alterations clearly indicate
damage caused by oxidative stress in neuronal circuits, they are
not necessarily causally linked to behavioral alterations, although
they may contribute to them.64 Although oxidative stress are
mostly in neurons, there were also indications of oxidative stress
in some glial cells in V animals. We also observed more activated
microglia and phagocytic microglial in the CA3 of V rats, as
compared with NV (Supplementary Figure S2c). The observed
oxidative damage are more prominent in neurons than glial cells
may be due to the latter ability to better compensate and repair
damage than neurons. This could be explained by the abundance
of reduced glutathione in glial cells than in neurons.65 We cannot
rule out a contribution of these cells to the vulnerability
phenotype.
Multiple studies have shown that Nrf2 is involved in numerous
pathological processes. Activating the Nrf2-Keap1 pathway with
chemical activators is beneﬁcial prior to/after intracerebral
hemorrhage or traumatic brain injury as well as in chemical/acute
Figure 3. Nrf2 alteration is necessary and sufﬁcient to induce vulnerability to depression. (a) Lipid peroxidation (MDA) was increased in Nrf2-null
mice (Nrf2− /− ) as compared with Nrf2+/+ (n= 6, for each). (b) Apical CA3 dendritic architecture was altered in Nrf2− /− mice. Alterations were
reversed following a 4-week Tempol (Tp) treatment (n= 6–7 mice). (c) Evaluation of depression-like phenotype as assessed with immobility time
in the forced swim test, sweet water consumption and HPA axis activity of Nrf2− /− and Nrf2+/+ mice, treated or not with Tempol (Tp),
submitted or not to 3 weeks of CMS (n= 6-9 mice). Note that Nrf2− /− mice were endogeneously in a vulnerable state, as CMS was sufﬁcient to
induce a depression-like phenotype. In contrast, CMS did not trigger a depression-like phenotype in Nrf2+/+ mice. Tempol treatment fully
reversed the vulnerability state of Nrf2− /− mice. (d) Treatment with the Nrf2 activator t-BHQ abolished the depression-like phenotype in V rats
(n= 6), as compared with vehicle-treated V rats (n= 8). (e) In vivo injection of BDNF siRNA in rat hippocampus decreased Nrf2 nuclear levels as
compared with control siRNA or saline (Sal) injections (n= 5–6). Microinjection of siRNA BDNF triggered an oxidative stress response as assessed
by lipid peroxidation. (f) In vivo microinjection of BDNF increased the translocation of Nrf2 to the nucleus compartment (n= 4). (g) SD in rats
decreased Nrf2 translocation to the compartment of nucleus. Hippocampal perfusion with 7,8-DHF (10 μM) increased Nrf2 translocation in
control and SD rats (C: n= 6–7; SD: n= 6–7). The results of statistical analyses are presented in Supplementary Table S1 C1-5. *Po0.05 vs Nrf2
+/+ mice, vs vehicle (Veh), vs siRNA control or vs C animals; aPo0.05 vs NV rats or vs saline (Sal) group; †Po0.05 vs the corresponding treated
group. See also Supplementary Figure S3a,b for cytosolic Nrf2 in in vivo siRNA condition; cytosolic Nrf2 in ex vivo condition and Supplementary
Table S2 C1-2 for statistical analysis. BDNF, brain-derived neurotrophic factor; CMS, chronic mild stress; DHF, dihydroxyﬂavone;
HPA, hypothalamic–pituitary–adrenal hyperactivity; NV, non-vulnerable; ROS, reactive oxygen species; SD, social defeat.
Figure 4. Restoring BDNF-dependent Nrf2 nuclear translocation re-establishes redox homeostasis, repairs neuronal damage and abolishes
vulnerability to depression. (a) Systemic injections of 7,8-DHF restored Nrf2 translocation to the nucleus and expression of sulﬁredoxin in V rats
(n= 7) at D11, as compared with vehicle-treated V animals (n= 6). (b) 7,8-DHF treatment restored the expression of the active form of Prx-2 in V
animals as compared with vehicle-treated animals (C: n= 5; NV: n= 6–7; V: n= 5–6). (c) Reversion of DNA oxidation [8-oxo-dG marker] by 7,8-
DHF in the ventral and dorsal hippocampus of vulnerable (V, n= 5) as compared with NV (n= 5), and control (C, n= 4) animals at D11.
Immunoﬂuorescence micrographs illustrating DNA oxidation in all subﬁelds of the ventral hippocampus of treated, or not, control (C), NV and V
animals (Dentate Gyrus: DG, CA3, CA1). Scale bars, 100 μm. (d) The total apical dendritic length of CA3 neurons and spine density was restored
in 7,8-DHF-treated V and NV animals, as compared with vehicle-treated animals. (e) Treatment with 7,8-DHF in animals identiﬁed as V at D11
(n= 6–7) completely prevented the occurrence of a depression-like phenotype following CMS (n= 8). The results of statistical
analyses are presented in Supplementary Table S1 D1-3. *Po0.05 vs C animals; aPo0.05 vs NV animals; †Po0.05 vs the corresponding
7,8-DHF-treated group. See also Supplementary Figure S3c-e for cytosolic Nrf2 or Keap1, neuroanatomical alterations and oxidative stress in
non-vulnerable, vulnerable or control animals treated, or not, with 7,8-DHF, 11 days after the SD and Supplementary Table S2 C3-4 for statistical
analysis. BDNF, brain-derived neurotrophic factor; CMS, chronic mild stress; DHF, dihydroxyﬂavone; NV, non-vulnerable; SD, social defeat.
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models of neurodegeneration.18,19,66 Here, we demonstrate that
Nrf2 dysfunction is also central to vulnerability to depression in a
double-hit scenario. Nrf2-null mice were endogenously in a
vulnerable state, as indicated by results showing that mild stress
was sufﬁcient to induce a depressive phenotype. Restoring Nrf2
function with an activator of Nrf2 (t-BHQ) or 7,8-DHF, regardless of
its mode of action, transformed V into NV animals, as reﬂected in
their abolished vulnerability to depression. Hence, permanent Nrf2
dysfunction is both necessary and sufﬁcient to induce a
permanent state of vulnerability to depression (although the
necessary and sufﬁcient conditions were tested in different
species: rats and mice, respectively). Because depression is
associated with most neurological disorders,13 it will be particu-
larly important to assess Nrf2 function in these pathologies. In
particular, we recently demonstrated that in a stress-epilepsy
double-hit scenario, only vulnerable animals developed
BDNF, oxidative stress and vulnerability to depression
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depression-like phenotype after the onset of epilepsy, suggesting
that a context including high allostatic load may favor the
development of depression in neurological disorders.35
Our data show that BDNF is involved in vulnerability to
depression rather than in depression per se, which may explain
why clinical data do not always support a direct correlation
between BDNF levels and depression.67 Since early-life adversity
leaves lasting epigenetic marks at the BDNF gene,68 and since the
stress disorders involve the epigenetic regulation of Rac1
following SD,64 epigenetic mechanisms may be involved in
BDNF/Nrf2-dependent vulnerability depression, at least in the
model used here.
In conclusion, our study paves the way for the identiﬁcation of
at-risk patients and preventive treatments. We have proposed that
BDNF can be used as a biomarker for vulnerability to depression
and that reinstating redox balance restores a normal phenotype.
More generally, the BDNF-Nrf2 pathway constitutes an interesting
therapeutic target (in particular with t-BHQ) for the treatment
of stress-related psychiatric disorders and neurodegenerative
diseases that are associated with pro-oxidant conditions.
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Figure 5. Summary scheme for vulnerability to depression after SD. A major stressful event leads to an early oxidative stress response, which
needs to be cleared by endogenous antioxidant processes. If oxidative stress persists, a vulnerability state to depression is produced. Low
BDNF levels in SD animals, during the acute phase, impair appropriate Nrf2 translocation, and the transcription of the downstream genes,
particularly sulﬁredoxin involved in the peroxiredoxin-2 regeneration leading to oxidative stress. In NV animals, the return to baseline BDNF
after SD enables normal Nrf2 function, with the activation of defense mechanisms, in particular, sulﬁredoxin to restore Prx-2 activity and H2O2
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